| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A A Lucian. Clinical presentation of hyperprolactinemia. The Journal of reproductive medicine. vol 44. issue 12 Suppl. 2000-02-09. PMID:10649815. |
in the absence of an identifiable and treatable underlying cause, hyperprolactinemia is generally treated with dopamine agonist medications. |
2000-02-09 |
2023-08-12 |
Not clear |
| D Oliv. Indications for hyperprolactinemia therapy. The Journal of reproductive medicine. vol 44. issue 12 Suppl. 2000-02-09. PMID:10649816. |
the vast majority of people with hyperprolactinemia can be treated medically with dopamine agonist medications. |
2000-02-09 |
2023-08-12 |
Not clear |
| J Webste. Dopamine agonist therapy in hyperprolactinemia. The Journal of reproductive medicine. vol 44. issue 12 Suppl. 2000-02-09. PMID:10649819. |
dopamine agonist therapy in hyperprolactinemia. |
2000-02-09 |
2023-08-12 |
Not clear |
| J Verhelst, R Abs, D Maiter, A van den Bruel, M Vandeweghe, B Velkeniers, J Mockel, G Lamberigts, P Petrossians, P Coremans, C Mahler, A Stevenaert, J Verlooy, C Raftopoulos, A Becker. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. The Journal of clinical endocrinology and metabolism. vol 84. issue 7. 1999-07-26. PMID:10404830. |
cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. |
1999-07-26 |
2023-08-12 |
Not clear |
| R G Pett. Prolactin and antipsychotic medications: mechanism of action. Schizophrenia research. vol 35 Suppl. 1999-07-21. PMID:10190227. |
since the release of prolactin is tonically inhibited by the hypothalamus, with dopamine acting as the prolactin release-inhibiting factor, any disruption of the connection between the hypothalamus and the pituitary gland is associated with hyperprolactinemia. |
1999-07-21 |
2023-08-12 |
Not clear |
| F C Albuquerque, D R Hinton, M H Weis. Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report. Journal of neurosurgery. vol 89. issue 6. 1998-12-08. PMID:9833836. |
hyperprolactinemia, with levels of prolactin as high as 150 ng/ml, is commonly associated with sellar tumors and is attributed to disruption of the normal delivery of dopamine to the adenohypophysis. |
1998-12-08 |
2023-08-12 |
Not clear |
| M da D Oliveira, R Cremonese, C Pizarr. Hyperprolactinemia associated to calcification of the pituitary stalk. Case report. Arquivos de neuro-psiquiatria. vol 56. issue 2. 1998-10-05. PMID:9698742. |
once other possible etiologies were excluded, we concluded that the calcification was probably related to hyperprolactinemia caused by interruption of the input of dopamine to the pituitary gland. |
1998-10-05 |
2023-08-12 |
Not clear |
| L L Bernardis, L L Bellinge. The dorsomedial hypothalamic nucleus revisited: 1998 update. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). vol 218. issue 4. 1998-09-03. PMID:9714072. |
the hyperprolactinemia in dmnl rats appears to be related to an attenuation of dopamine (da). |
1998-09-03 |
2023-08-12 |
rat |
| R Abs, J Verhelst, D Maiter, K Van Acker, F Nobels, J L Coolens, C Mahler, A Becker. Cabergoline in the treatment of acromegaly: a study in 64 patients. The Journal of clinical endocrinology and metabolism. vol 83. issue 2. 1998-02-27. PMID:9467544. |
cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients with hyperprolactinemia. |
1998-02-27 |
2023-08-12 |
Not clear |
| A G Nasello, M L Vanzeler, E H Madureira, L F Felici. Effects of acute and long-term domperidone treatment on prolactin and gonadal hormone levels and sexual behavior of male and female rats. Pharmacology, biochemistry, and behavior. vol 58. issue 4. 1998-01-30. PMID:9408218. |
domperidone (domp), a dopamine d2 blocker that is unable to cross the blood-brain barrier, is an experimental tool used to induce hyperprolactinemia. |
1998-01-30 |
2023-08-12 |
rat |
| S Patel, S Freedman, K L Chapman, F Emms, A E Fletcher, M Knowles, R Marwood, G Mcallister, J Myers, N Curtis, J J Kulagowski, P D Leeson, M Ridgill, M Graham, S Matheson, D Rathbone, A P Watt, L J Bristow, N M Rupniak, E Baskin, J J Lynch, C I Raga. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. The Journal of pharmacology and experimental therapeutics. vol 283. issue 2. 1997-12-08. PMID:9353380. |
these results show that dopamine d4 receptor antagonism in the brain does not result in the same neurochemical consequences (increased dopamine metabolism or hyperprolactinemia) observed with typical neuroleptics. |
1997-12-08 |
2023-08-12 |
human |
| M Moro, C Maraschini, F Cavagnin. Dopamine infusion enhances the adrenocorticotropic hormone and cortisol response to metoclopramide in hyperprolactinemic patients but not in normal subjects. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 11. issue 3. 1997-10-02. PMID:9209895. |
based on the facts that prolactin and adrenocorticotropic hormone (acth) each seem to influence the secretion of the other, that dopamine is the established inhibitory factor for prolactin secretion and negatively modulates acth release, and finally that alterations of the central dopaminergic tone have been postulated in tumorous hyperprolactinemia, we studied the effects of pharmacological manipulations of the dopaminergic system on acth and cortisol secretion in patients bearing a prolactinoma and in normal subjects. |
1997-10-02 |
2023-08-12 |
human |
| M Moro, C Maraschini, F Cavagnin. Dopamine infusion enhances the adrenocorticotropic hormone and cortisol response to metoclopramide in hyperprolactinemic patients but not in normal subjects. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 11. issue 3. 1997-10-02. PMID:9209895. |
these findings support the concept of an inhibitory role exerted by dopamine and are compatible with a stimulatory influence exerted by prolactin on corticotropin-releasing hormone and acth secretion, and also favor the view of a reduced central dopaminergic tone in patients with tumorous hyperprolactinemia. |
1997-10-02 |
2023-08-12 |
human |
| M A Kelly, M Rubinstein, S L Asa, G Zhang, C Saez, J R Bunzow, R G Allen, R Hnasko, N Ben-Jonathan, D K Grandy, M J Lo. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. vol 19. issue 1. 1997-10-02. PMID:9247267. |
pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine d2 receptor-deficient mice. |
1997-10-02 |
2023-08-12 |
mouse |
| J C Shyu, C Y Chu, S L Duh, J Y Liu, C L Chan. Nucleus accumbens dopaminergic mediation of protection against gastric mucosal ulcerations by cold-restraint stress in the male hyperprolactinemic rats. The Chinese journal of physiology. vol 40. issue 1. 1997-07-21. PMID:9170554. |
an investigation was undertaken to study the relationship between change in gastric lesion induced by cold-restraint stress and brain dopamine (da) activity in male rat with chronic hyperprolactinemia. |
1997-07-21 |
2023-08-12 |
rat |
| P S Mohankumar, S M Mohankumar, S K Quadri, J L Voog. Chronic hyperprolactinemia and changes in dopamine neurons. Brain research bulletin. vol 42. issue 6. 1997-07-18. PMID:9128918. |
chronic hyperprolactinemia and changes in dopamine neurons. |
1997-07-18 |
2023-08-12 |
rat |
| P S Mohankumar, S M Mohankumar, S K Quadri, J L Voog. Chronic hyperprolactinemia and changes in dopamine neurons. Brain research bulletin. vol 42. issue 6. 1997-07-18. PMID:9128918. |
after 6 months of hyperprolactinemia, dopamine (da) concentrations in the median eminence (me) increased by 84% over the control group. |
1997-07-18 |
2023-08-12 |
rat |
| B M Biller, M E Molitch, M L Vance, K B Cannistraro, K R Davis, J A Simons, J R Schoenfelder, A Klibansk. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. The Journal of clinical endocrinology and metabolism. vol 81. issue 6. 1996-12-11. PMID:8964874. |
cabergoline is a long-acting dopamine agonist specific for the d2 receptor that is more effective and better tolerated than bromocriptine in women with microadenomas or idiopathic hyperprolactinemia. |
1996-12-11 |
2023-08-12 |
Not clear |
| J D Veldhui. Neuroendocrine mechanisms mediating awakening of the human gonadotropic axis in puberty. Pediatric nephrology (Berlin, Germany). vol 10. issue 3. 1996-12-04. PMID:8792395. |
when the pathophysiology of hypogonadism originates exclusively in a failed gnrh pulse generator, then either treatment of the primary disease process where possible (e.g., by refeeding in starvation, improved metabolic control in diabetes mellitus, dopamine agonist treatment in hyperprolactinemia, etc) and/or treatment with pulsatile gnrh (e.g., in kallmann's syndrome, isolated hypothalamic lesions, etc.) |
1996-12-04 |
2023-08-12 |
human |
| N V Boĭko, T S Kolmakova, E N Nesterenko, F Ia Groĭsber. [Characteristics of prolactin secretion in response to different degrees of lesions of the vestibular analyzer]. Kosmicheskaia biologiia i aviakosmicheskaia meditsina. vol 25. issue 6. 1996-03-08. PMID:8577166. |
hyperprolactinemia during central vestibular dysfunction is viewed as a manifestation of dopamine deficiency of the tuberoinfundibular area. |
1996-03-08 |
2023-08-12 |
Not clear |